Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
A multi-center, prospective clinical study to evaluate the efficacy and safety of R-GDP plus
PD-1 monoclonal antibody in the treatment of refractory or relapsed peripheral T cell
lymphoma not otherwise specified and Angioimmunoblastic T-cell lymphoma, which has previously
shown promising efficacy.
Phase:
N/A
Details
Lead Sponsor:
Ou Bai, MD/PHD
Collaborators:
China-Japan Union Hospital, Jilin University Second Hospital of Jilin University